1. Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial
Figure 2 | Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial. In this phase III randomized controlled trial, relative efficacies of chemotherapy (cisplatin plus gemcitabine) versus erlotinib as first-line treatments of patients with advanced-stage non-small-cell lung cancer were investigated. These data suggest that physicians are more accurate in reporting adverse effects that are expected with each specific treatment — nausea and vomiting with cisplatin plus gemcitabine, and diarrhoea with erlotinib25.
Di. Maio, M. et al. (2016) Patient-reported outcomes in the evaluation of toxicity of anticancer treatments Nat. Rev. Clin. Oncol. doi: /nrclinonc